885518-47-8

Basic information

• Product Name: Methyl 4-bromo-6-(1H)-ind...
• Synonyms: Methyl 4-bromo-6-(1H)-ind...;Methyl 4-broMo-1H-indazole-6-carboxylate;Methyl 4-broMo-6-(1H)-indazole carboxylate;1H-Indazole-6-carboxylicacid,4-broMo-,Methylester;4-BroMo-1H-indazole-6-carboxylic acid Methyl ester
• CAS NO: 885518-47-8
• Molecular Formula: C₉H₇BrN₂O₂
• Molecular Weight: 255.06808
• Mol File: 885518-47-8.mol

Chemical Properties

• Boiling Point: 395.9±22.0 °C(Predicted)
• Appearance: /
• Density: 1.709
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 11.21±0.40(Predicted)
• CAS DataBase Reference: Methyl 4-bromo-6-(1H)-ind...(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 4-bromo-6-(1H)-ind...(885518-47-8)
• EPA Substance Registry System: Methyl 4-bromo-6-(1H)-ind...(885518-47-8)

Safety Data

• Hazardous Substances Data: 885518-47-8(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
Methyl 4-bromo-6-(1H)-indazole-1-carboxylate is used as an intermediate in the synthesis of various organic compounds. Its unique structure and reactivity allow for the formation of new chemical bonds and the creation of diverse molecular structures.
Used in Pharmaceutical Research:
Methyl 4-bromo-6-(1H)-indazole-1-carboxylate is used as a starting material or intermediate in the development of new pharmaceuticals. Its properties and reactivity make it a valuable component in the synthesis of potential drug candidates.
Used in Drug Production:
Methyl 4-bromo-6-(1H)-indazole-1-carboxylate is used as an important intermediate in the production of various drugs. Its unique structure and reactivity contribute to the development of new therapeutic agents with improved efficacy and safety profiles.
Used in Biological and Pharmacological Studies:
Methyl 4-bromo-6-(1H)-indazole-1-carboxylate may exhibit biological activities and pharmacological effects that make it valuable for further study. Its potential applications in this area could lead to the discovery of new therapeutic agents and a better understanding of its mechanisms of action.

Upstream product

• 882679-96-1 methyl 4-bromo-1H-indole-6-carboxylate 
• 223519-11-7 methyl 3-amino-5-bromo-4-methylbenzoate 
• 223519-08-2 methyl 3-bromo-4-methyl-5-nitrobenzoate 
• 34545-20-5 3-bromo-4-methyl-5-nitro-benzoic acid 
• 96-98-0 4-methyl-3-nitrobenzoic acid 

Downstream Products

• 1285532-20-8 C₂₁H₂₅N₅O 
• 1285531-68-1 1-(4-(6-(N-(2-(piperidin-1-yl)ethyl)aminocarbonyl)-1H-indazol-4-yl)phenyl)-3-(3-(trifluoromethoxy)phenyl)urea 
• 885523-43-3 4-bromo-1H-indazole-6-carboxylic acid 
• 885518-53-6 4-bromo-1H-indazol-6-amine 
• 1527007-77-7 methyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole-6-carboxylate 
• 170487-40-8 1H-indazole-6-carboxylic acid methyl ester 
• 1638772-21-0 methyl 4-bromo-2-methyl-2H-indazole-6-carboxylate 
• 1638759-79-1 methyl 4-bromo-1-methyl-1H-indazole-6-carboxylate 

Relevant articles and documents

SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE

The present invention provides compounds of Formula (I) or a subgeneric structure or species thereof, or a pharmaceutically acceptable salt, ester, solvate, and/or prodrug thereof, and methods and compositions for treating or ameliorating abnormal cell pr

CARBOXY SUBSTITUTED (HETERO) AROMATIC RING DERIVATIVES AND PREPARATION METHOD AND USES THEREOF

Carboxy-substituted (hetero)aryl derivatives, pharmaceutical compositions comprising these compounds, and methods of preparing such compounds and compositions are provided. The compounds or compositions are useful in inhibiting xanthine oxidase and urate anion transporter 1, and also can be used in the treatment or prevention of diseases associated with high blood uric acid level in mammals, especially humans.

Synthesis of substituted 4-(1H-indol-6-yl)-1H-indazoles as potential PDK1 inhibitors

The development of a preparative route to a series of novel 4-(1H-indol-6-yl)-1H-indazole compounds as potential PDK1 inhibitors is described. The synthetic strategy centres on the late-stage Suzuki cross-coupling of N-unprotected indazole and indole frag

COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly di